Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,827 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07448662 | Local Treatment Strategies for Brain Metastases of Colorectal Cancer(COLBRAIN) | active not recruiting | — | 700 | Blokhin's Russian Cancer Research CenterOTHER | 2 | Mar 4, 2026 | clinicaltrials |
| NCT04884360 | D9319C00001- 1L OC Mono Global RCT(MONO-OLA1) | active not recruiting | Phase 3 | 366 | AstraZenecaINDUSTRY | 10 | Mar 2, 2026 |
| clinicaltrials |
| NCT01602380 | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.(FALCON) | completed | Phase 3 | 462 | AstraZenecaINDUSTRY | 20 | Feb 27, 2026 | clinicaltrials |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | completed | Phase 3 | 1,334 | TakedaINDUSTRY | 21 | Feb 27, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT03675737 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | completed | Phase 3 | 1,579 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Feb 27, 2026 | clinicaltrials |
| NCT07421141 | De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer(Opti-HER2) | active not recruiting | Phase 2 | 186 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03976362 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | completed | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Feb 25, 2026 | clinicaltrials |
| NCT04059484 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer(AMEERA-3) | terminated | Phase 2 | 367 | SanofiINDUSTRY | 23 | Feb 24, 2026 | clinicaltrials |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma(CLEAR) | active not recruiting | Phase 3 | 1,069 | Eisai Inc.INDUSTRY | 20 | Feb 23, 2026 | clinicaltrials |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | completed | Phase 3 | 1,060 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Feb 20, 2026 | clinicaltrials |
| NCT05005442 | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) | completed | Phase 2 | 192 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Feb 19, 2026 | clinicaltrials |
| NCT03332017 | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma(ROSEWOOD) | completed | Phase 2 | 217 | BeiGeneINDUSTRY | 17 | Feb 18, 2026 | clinicaltrials |
| NCT03143153 | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin(CheckMate 648) | completed | Phase 3 | 970 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 17, 2026 | clinicaltrials |
| NCT02000622 | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.(OlympiAD) | completed | Phase 3 | 302 | AstraZenecaINDUSTRY | 19 | Feb 13, 2026 | clinicaltrials |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer(RECITE) | completed | Phase 3 | 165 | AmgenINDUSTRY | 20 | Feb 11, 2026 | clinicaltrials |
| NCT07403916 | Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer | active not recruiting | — | 90 | P. Herzen Moscow Oncology Research InstituteOTHER_GOV | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07400094 | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC(NeoCamre-HN) | not yet recruiting | Phase 2 | 50 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07401498 | Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).(LNDNSCLC-RUS) | enrolling by invitation | N/A | 1,000 | Regional Clinical Oncology DispensaryOTHER_GOV | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT06705530 | A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders | completed | Phase 1 / Phase 2 | 58 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER) | active not recruiting | Phase 3 | 453 | Eli Lilly and CompanyINDUSTRY | 21 | Feb 6, 2026 | clinicaltrials |
| NCT02747004 | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer(Next MONARCH 1) | active not recruiting | Phase 2 | 234 | Eli Lilly and CompanyINDUSTRY | 14 | Feb 6, 2026 | clinicaltrials |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | completed | Phase 3 | 794 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 5, 2026 | clinicaltrials |
| NCT04776148 | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | completed | Phase 3 | 563 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Feb 5, 2026 | clinicaltrials |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | completed | Phase 3 | 617 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Feb 4, 2026 | clinicaltrials |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer(MONARCH 3) | active not recruiting | Phase 3 | 493 | Eli Lilly and CompanyINDUSTRY | 22 | Feb 3, 2026 | clinicaltrials |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)(LEAP-001) | completed | Phase 3 | 842 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Feb 2, 2026 | clinicaltrials |
| NCT05061823 | Bintrafusp Alfa Program Rollover Study | completed | Phase 3 | 22 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | Feb 2, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer(T-REX) | completed | — | 3,647 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 7 | Jan 29, 2026 | clinicaltrials |
| NCT07375563 | Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma(NB-NK-2026) | recruiting | Phase 3 | 5 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
| NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies | recruiting | Phase 2 / Phase 3 | 64 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT06114498 | Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction | active not recruiting | — | 240 | National Medical Research Center for Therapy and Preventive MedicineOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03456063 | A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Jan 22, 2026 | clinicaltrials |
| NCT04165317 | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer(CREST) | active not recruiting | Phase 3 | 1,068 | PfizerINDUSTRY | 14 | Jan 22, 2026 | clinicaltrials |
| NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years(ODYSSEY) | recruiting | Phase 4 | 2,076 | GuerbetINDUSTRY | 8 | Jan 22, 2026 | clinicaltrials |
| NCT04818671 | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis(ADAPTSC+) | completed | Phase 3 | 184 | argenxINDUSTRY | 12 | Jan 22, 2026 | clinicaltrials |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | active not recruiting | Phase 3 | 437 | Bristol-Myers SquibbINDUSTRY | 14 | Jan 21, 2026 | clinicaltrials |
| NCT04763642 | The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone | completed | N/A | 320 | State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical HospitalOTHER_GOV | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07292168 | A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1(TAGNOT) | recruiting | Phase 1 / Phase 2 | 58 | Kidney Cancer Research BureauOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05529316 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | active not recruiting | Phase 2 | 150 | Agenus Inc.INDUSTRY | 10 | Jan 16, 2026 | clinicaltrials |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)(STIMULUS-MDS2) | terminated | Phase 3 | 530 | Novartis PharmaceuticalsINDUSTRY | 36 | Jan 13, 2026 | clinicaltrials |
| NCT03474107 | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | completed | Phase 3 | 608 | Astellas Pharma Global Development, Inc.INDUSTRY | 19 | Jan 9, 2026 | clinicaltrials |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis(TRANSFORM-2) | active not recruiting | Phase 3 | 330 | AbbVieINDUSTRY | 30 | Jan 9, 2026 | clinicaltrials |
| NCT06429163 | Pre-incisional Wound INfiltration and Hypogastric PLEXus Block Using Ropivacaine in Laparoscopic Myomectomy(WINPLEX) | completed | N/A | 207 | Saint Petersburg State University, RussiaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials